Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic BM-MSC for ischemic digital ulcers in systemic sclerosis
NL-OMON47582Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of allogeneic bone marrow-derived mesenchymal stromal cells in systemic sclerosis (SSc) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Treatment toxicity at 12 weeks. Started Oct 2021; status: recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON47582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47582.